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Abstract
Introduction
Colorectal cancer screening rates are low throughout the
United States. Colonoscopy has been recommended as a
cost-effective strategy for colorectal cancer screening and
prevention. We evaluated New Mexico’s capacity to
increase the prevalence of colorectal cancer screening
using colonoscopy.
Methods
We identified New Mexican gastroenterologists from
state licensing data and from endoscopic manufacturers.
We surveyed gastroenterologists on their weekly number
of colonoscopies, capacity for additional screening colono-
scopies, and barriers to increasing capacity. We used cen-
sus data, published data on the yield of screening
colonoscopy, and professional society guidelines for 
cancer/polyp surveillance to estimate the additional
colonoscopies required to increase the state’s prevalence of
endoscopic screening.
Results
Forty gastroenterologists, representing all 11 group prac-
tices in the state, and nine of 12 solo practitioners respond-
ed. They estimated that their weekly procedure capacity
could be increased by 41%, from 832 to 1174 colonoscopies.
We estimated an annual capacity increase of 14,880 proce-
dures, which could increase the prevalence of endoscopic
colorectal cancer screening from the current 35% to about
50% over five years. Lack of support staff, space, and physi-
cians were barriers to increasing screening.
Conclusions
Implementing a screening colonoscopy strategy could
achieve the goal of a higher level of colorectal screening.
However, achieving more universal screening would
require additional testing modalities.
Introduction
Colorectal cancer is the third most frequently diagnosed
cancer in New Mexico and the second leading cause of can-
cer death (1). Randomized controlled trials of fecal occult
blood testing (FOBT) have shown that screening reduces
the incidence and mortality of colorectal cancer (2-4).
Flexible sigmoidoscopy has also been shown to reduce col-
orectal cancer mortality in well-designed case-control
studies (5,6). Professional organizations have identified
colorectal cancer screening as an effective, high-priority
intervention (7-10). Acceptable modalities include FOBT,
flexible sigmoidoscopy, colonoscopy, and double-contrast
barium enema. 
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Despite those supportive practice guidelines, colorectal
cancer screening rates remain low. National data show
that just over 50% of adults aged 50 years and older are
considered to be appropriately screened for colorectal can-
cer with either a FOBT within one year or an endoscopic
procedure within 10 years (11,12). In New Mexico, 2001
survey data from the Centers for Disease Control and
Prevention’s (CDC’s) Behavioral Risk Factor Surveillance
System (BRFSS) reported that only 23.2% of adults aged
50 years and older had undergone FOBT testing in the
previous two years and that 34.5% had undergone a flexi-
ble sigmoidoscopy or colonoscopy in the previous five years
(13). The BRFSS survey did not obtain information about
radiographic screening tests. Overall, only 48% of the
adult population was considered currently screened
(analysis by the New Mexico BRFSS Unit, July 2003); this
likely is an overestimate given the limited concordance of
the BRFSS colorectal cancer screening questions with
medical records (14) and the potential selection bias intro-
duced by the telephone survey design.
Efforts to improve screening rates have included
celebrity endorsements by Katie Couric (15), the CDC’s
Screen for Life campaign (16), the American Cancer
Society’s “Polyp Man” public service announcements
(17), and President Clinton’s 2000 declaration that
March would henceforth be National Colorectal Cancer
Awareness Month (18). Medicare began reimbursing for
colorectal cancer screening with FOBT and flexible sig-
moidoscopy in 1998 and has reimbursed screening
colonoscopy at 10-year intervals for average-risk adults
since July 2001 (19). The National Center for Quality
Assurance has established a new Health Plan Employer
Data and Information Set measure of colorectal cancer
screening performance standards for health care plans
beginning in 2004 (20,21).
Although there is no direct evidence for its screening effi-
cacy, colonoscopy is the most accurate diagnostic test and
offers the potential to remove premalignant growths.
Winawer and colleagues estimated that colonoscopy could
reduce the incidence of colorectal cancer by a range of 76%
to 90% (22). Economic analyses have also found that
colonoscopy is a cost-effective screening strategy for col-
orectal cancer (23-25). The American College of
Gastroenterology practice guidelines recommend
colonoscopy to be the first screening option (26). However,
experts have questioned the feasibility of increasing
screening through colonoscopy because the number of
colonoscopists and infrastructure needed to screen the
population may be inadequate (9). We conducted a survey
of New Mexican gastroenterologists to determine the fea-
sibility of implementing a colonoscopic screening strategy
to improve statewide screening rates.
Methods
The Colorectal Cancer Screening Working Group of the
Clinical Prevention Initiative (CPI) evaluated screening
capacity by conducting a mailed survey of endoscopists in
New Mexico. The CPI membership, composed of public
health and health care professionals, is supported by the
New Mexico Department of Health and the New Mexico
Medical Society to promote more effective delivery of 
practice-based preventive services throughout the state of
New Mexico.
Subjects 
We identified endoscopists in New Mexico by using data
from the Board of Medical Examiners, contacting manu-
facturers of endoscopic equipment, and obtaining the
membership lists of a statewide gastroenterology journal
club, the New Mexico Medical Society, and the American
Medical Association. Eligible subjects for this analysis
were gastroenterologists actively practicing in New
Mexico, which included 40 gastroenterologists practicing
in one of the 11 group practices and 12 solo practitioners.
Survey
The CPI colorectal cancer group developed a brief survey
to obtain information about endoscopic capacity, including
colonoscopies and flexible sigmoidoscopies (Table 1).
Questions were based on literature review, the BRFSS,
and the clinical experience of the CPI colorectal cancer
group, which included two gastroenterologists and two
internists who performed sigmoidoscopy. Revisions were
based on pilot testing the survey with clinical colleagues
and other members of the CPI. The survey was conducted
between October and December 2001. Subjects were
mailed a letter introducing the survey and asking for their
participation. The survey was printed on a postcard with a
return address and postage. For nonrespondents, we fol-
lowed up with telephone calls and repeat mailings two
weeks after the initial contact.
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Statistical analysis 
We used simple, descriptive nonparametric statistics to
estimate the weekly median number of procedures per-
formed by endoscopists in group practice and solo practice
and the estimated weekly potential increase in capacity.
Endoscopic capacity. We determined the number of
additional screening colonoscopies that could be per-
formed using survey responses. We averaged responses
when multiple members of a group practice completed the
survey and provided different estimates for the weekly
number of baseline and additional procedures performed
by the practice. We imputed the weekly number of base-
line and additional colonoscopies for the solo-practitioner
nonrespondents using data from the responding solo prac-
titioners. For the annual number of colonoscopies, we
assumed that endoscopists performed procedures for 40
weeks. We performed similar estimates for the number of
flexible sigmoidoscopies.
Volume of colonoscopies. We modeled the number of
procedures required for a statewide screening colonoscopy
strategy. To identify the number of subjects potentially eli-
gible for colonoscopic screening, we used data from the
2000 United States Census for New Mexico that reported
468,000 resident adults aged 50 to 85 (27). Based on the
census data, we evaluated the additional number of
screening colonoscopies required to increase the preva-
lence of current screening by 5% (23,400 additional people
being screened), 10% (46,800), 15% (70,200), 20% (93,600),
and 25% (117,000) during a five-year period. We assumed
that the additional screening procedures would be per-
formed in equal numbers during the five-year period. We
then modeled the number of surveillance procedures that
would be required following the initial screening
colonoscopy. We used clinical data on the yield of colorec-
tal cancers and adenomatous polyps from a recent large
Department of Veterans Affairs (VA) colonoscopic screen-
ing trial (28) and consensus guidelines for the timing of
surveillance procedures (10).
• Colorectal cancer detection level: 1%
• Adenomatous polyp detection level: 37%
• Advanced (villous, dysplastic, >1 cm, >2 polyps) polyp
level: 15%
• Surveillance following colorectal cancer detection: 6
months and 3 years
• Surveillance following 1–2 adenomatous polyps <10 mm:
5 years
• Surveillance following advanced polyp: 3 years
We assumed that half of the cancers diagnosed in the
fifth year would have a six-month surveillance colonoscopy
that same year. The colonoscopic screening trial had a
higher proportion of subjects with positive family history
of colorectal cancer than the general population and may
have overestimated the yield of screening. Results from an
employee-health colonoscopic screening program did show
a lower yield than the VA study (29). Therefore, we per-
formed a sensitivity analysis by reducing the expected
rates of detected colorectal cancers and adenomatous
polyps by approximately 50%.
We entered survey data into a Microsoft Access
(Microsoft Corporation, Seattle, Wash) database. We per-
formed statistical analyses with SAS (SAS Institute, Inc,
Cary, NC) (30).
Results
We received procedure information from nine of 12 solo
practitioners and all 11 group practices, representing 40
endoscopists (two to eight practitioners per group).
Physicians and practices were based in 12 different coun-
ties. Ten of 11 group practices and six of 12 solo practi-
tioners were located in urban areas, defined by the Census
Bureau as having population densities >1000 per square
mile (31). Table 2 shows the numbers of procedures cur-
rently being performed weekly and the weekly capacity for
additional procedures, which were stratified by type of
practice. Overall, gastroenterologists reported performing
832 colonoscopies a week; they estimated being able to
increase their capacity by an additional 342 (41%) proce-
dures each week.
Assuming a 40-week work year, each endoscopist in
group practice could perform an estimated 252 addi-
tional colonoscopies every year and solo practitioners
could perform an estimated 400 additional colono-
scopies. Statewide, endoscopists could perform an esti-
mated 13,680 additional colonoscopic procedures each
year. If the nonresponding solo practitioners performed
similarly to those completing the survey, the estimated
annual additional capacity for colonoscopy would be
14,880 procedures.
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We show the estimated number of additional colono-
scopies required to increase screening prevalence by 5%,
10%, 15%, 20%, and 25% during a five-year period in Table
3. The total number of procedures includes screening pro-
cedures based on the 2000 New Mexico census and 
surveillance procedures based on the yield of cancer and
adenomatous polyps detected with screening. The second
column of numbers reflects the yield of advanced neoplasia
based on the VA study data from Lieberman and col-
leagues. The third column is a sensitivity analysis showing
the estimated number of colonoscopies if the cancer yield
was 0.5% and the overall yield of adenomatous polyps was
20%. If all patients with adenomatous polyps underwent
colonoscopic surveillance at three years (rather than just
patients with advanced neoplasia), the annual number of
procedures would be increased by about 5%. Overall, a
screening colonoscopy strategy could increase the preva-
lence of current colorectal cancer screening by about 15%.
Although our analyses focused on colonoscopies, we also
obtained information on flexible sigmoidoscopy. All but
one of the group practices performed flexible sigmoido-
scopies, but only five of the solo practitioners performed
them. Overall, however, only 165 procedures were per-
formed weekly; respondents estimated that they could per-
form an additional 188 procedures.
The barriers to performing additional endoscopic tests
are shown in Table 4. Only one group practice reported no
barriers to performing additional procedures, and four solo
practitioners reported no barriers. Lack of support staff,
space (for procedures and/or recovery room), and physi-
cians were the most frequently cited problems for the
group and solo practices.
Discussion
New Mexico gastroenterologists responding to our sur-
vey estimated having the capacity to increase their week-
ly number of colonoscopies by about 41%, from 832 to 1174.
This substantial increase could raise the prevalence of cur-
rent endoscopic screening by approximately 15% within
five years. The most recent BRFSS data report that 35% of
New Mexican adults are currently screened by endoscopy;
thus, the increased endoscopic capacity would be just suf-
ficient to achieve 50% colorectal cancer screening.
However, this level of screening would still be far short of
the 70% to 90% screening reported for mammography,
Papanicolaou (Pap) smears, and prostate-specific antigen
(PSA) tests (32,33). Additional recommended screening
modalities, including FOBT, flexible sigmoidoscopy, and
radiological studies would be needed to achieve a higher
level of screening (7,8).
Rex and Lieberman modeled a strategy for implement-
ing colonoscopy as the preferred screening procedure in
the United States (9). Based on a 10-year screening inter-
val and assuming that 10% of the adult population aged 50
to 70 would be screened every year, they estimated an
annual need for 7.7 million colonoscopies. After reducing
this number for patients with significant comorbidities,
noncompliance, and current screening, they estimated
that approximately 2.56 million additional colonoscopies
would need to be performed. Based on a government
report that 4.4 million colonoscopies were performed in
1999, Rex and Lieberman concluded that implementing
screening colonoscopy would require a 58% increase in
capacity. This figure may be an underestimation because
they modeled screening only until age 70. Given that the
incidence of colorectal cancer increases steadily with age
(34) and that screening could appropriately be offered until
age 80 (35), the actual number of additional colonoscopies
could be quite higher.
Even if Rex and Lieberman correctly estimated the num-
ber of additional procedures to fully implement screening
colonoscopy, the demand in New Mexico would likely
exceed the capacity of the state’s endoscopists — despite
their already high level of productivity. Endoscopists in
New Mexico reported performing about 16 to 20 colono-
scopies weekly, which compares quite favorably with data
obtained from the National Cancer Institute’s (NCI’s)
nationwide Survey of Colorectal Cancer Screening
Practices. The 346 gastroenterologists responding to the
survey, conducted between November 1999 and April
2000, performed an average of only 31.7 colonoscopies
monthly, including 12.4 for screening (36).
Rex and Lieberman acknowledged that increasing the
level of colonoscopies would be challenging (9). One of their
solutions was for gastroenterologists to perform 50% fewer
flexible sigmoidoscopies to make time to perform colono-
scopies (9). They cited Medicare data showing that 543,502
flexible sigmoidoscopies were performed in 2000. The
nationwide NCI survey estimated that gastroenterologists
performed 25% of sigmoidoscopies, which suggests that
nearly 70,000 fewer procedures could be performed in just
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the Medicare population alone (36). However, this survey
indicated that sigmoidoscopies comprised about 30% of the
colorectal endoscopic procedures performed by gastroen-
terologists. Our data showed that sigmoidoscopy 
comprised only 16% of the lower endoscopic procedures
performed by gastroenterologists in New Mexico, implying
practice patterns had already changed substantially.
Further reductions in performing sigmoidoscopy may not
be feasible, especially because many of the sigmoidoscopic
procedures are diagnostic.
Another strategy for implementing screening
colonoscopy would be to increase the number of procedures
performed by other medical providers. The NCI survey
reported that general surgeons performed 30% of colono-
scopies (36). However, on average, the 251 general sur-
geons performed fewer than eight colonoscopies monthly,
including about three screening colonoscopies. While near-
ly half of the gastroenterologists performed at least 10
screening colonoscopies monthly, only 6% of general sur-
geons reached this level. The NCI survey also obtained
data on colorectal cancer screening practices by primary
care physicians (37). Among the 1235 respondents, fewer
than 5% of primary care providers reported performing
colonoscopy, and most of them performed fewer than five
procedures monthly. Although 29% of primary care
respondents performed sigmoidoscopy, fewer than 20%
performed more than 10 procedures monthly.
Increasing screening colonoscopy by having general sur-
geons and primary care physicians perform these 
procedures does not seem to be a feasible strategy for New
Mexico. When we conducted our survey, endoscopic equip-
ment manufacturers provided us information on all 
practices that had purchased equipment for performing col-
orectal procedures. In addition to gastroenterologists, we
also identified surgeons and primary care physicians as
owners of endoscopic equipment. Three of the eight 
colorectal cancer surgeons in the state identified as per-
forming colonoscopies responded to the survey; they were
performing 18 colonoscopies weekly and estimated that they
could increase their capacity by 12 weekly. None of the 28
primary care providers who performed endoscopy reported
performing colonoscopy. Only six primary care endoscopists
reported performing five or more (maximum eight) flexible
sigmoidoscopies weekly; the majority performed less than
two. Another problem with relying on nongastroenterolo-
gists to perform endoscopy is that their low procedure vol-
ume may be associated with diminished proficiency (38).
Rex and Lieberman further noted that increasing capac-
ity for screening colonoscopy would require more efficiency
in endoscopy suites (9). Our respondents consistently
reported that limited space and support staff were barriers
to performing more procedures. Our respondents also
reported that having more physicians would help improve
capacity. Strategies to increase the number of gastroen-
terologists would likely target a training program; New
Mexico does have a university gastroenterology fellowship
program. However, Rex and Lieberman questioned the
wisdom of training more endoscopists because accurate,
cost-effective, noninvasive tests — such as virtual
colonoscopy or fecal DNA assays — are likely to be used
increasingly, thus reducing the need for screening colono-
scopies (9). Another barrier facing New Mexico is a rela-
tively impoverished population with a high proportion of
uninsured adults (39); financial incentives may also be
necessary to attract and retain specialists. Although there
is little data supporting the practice, nonphysicians could
also be trained to perform colonoscopy (40).
Our study had some important limitations. We were
generally unable to validate the self-reported weekly num-
ber of procedures performed by each practice or solo prac-
titioner. However, one group of three gastroenterologists,
who estimated that they annually performed 3000 proce-
dures, also reviewed their billing records for the previous
year. These data showed that they had overestimated
their current capacity by 10% — they actually performed
only 2760 procedures. The estimated increased capacity
also depends upon the respondents being able to accurate-
ly assess the practice’s ability to perform additional tests,
which could not be validated. However, if other practices
similarly overestimated their current capacity, then the
estimates for the absolute number of additional proce-
dures could also be inflated. 
Another potential limitation was that we used a simpli-
fied model. On the demand side, we assumed that patients
would be compliant with surveillance-testing recommen-
dations and that the population would be stable. On the
supply side, we assumed that the number of gastroen-
terologists in the state would be stable. We also assumed
that the supply of endoscopists would be matched with
patients needing procedures. However, New Mexico has
problems retaining specialists (41), and even having a suf-
ficient number of gastroenterologists may not ensure com-
prehensive screening coverage. In New Mexico, access to
care may be severely limited by geographic distance. New
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Mexico is a large, mostly rural state; almost all of the gas-
troenterologists practice in urban areas. Nonetheless, our
intention was not to precisely estimate screening capacity
but rather to provide a general assessment of the feasibil-
ity of implementing screening colonoscopy, including iden-
tifying provider barriers.
We conclude that New Mexico has the colonoscopic
capacity to substantially increase the prevalence of
adults with current colorectal cancer screening. The state
could probably achieve a level of 50% current endoscopic
screening by colonoscopy alone. However, New Mexico
lacks the capacity to implement a fully comprehensive
screening colonoscopy strategy. Efforts to achieve more
universal screening would also require additional modal-
ities such as FOBT, flexible sigmoidoscopy, and barium
enema in addition to health care policies requiring
screening coverage. More efficient use of colonoscopy
would also be necessary, including withholding 
colonoscopic screening from patients with limited life
expectancy (7), performing surveillance colonoscopy at
appropriate intervals (42), and considering a single life-
time-screening colonoscopy strategy (43).
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Tables
Table 1. Questions for Survey of Gastroenterologists on
Colonoscopy Screening Capacity, New Mexico, 2001
1. How many endoscopists work in your practice?
2. How many perform colonoscopy?
3. How many perform sigmoidoscopy?
4. During an average week, how many colonoscopies do you 
perform?
5. During an average week, how many colonoscopies are 
performed in your practice?
6. During an average week, how many sigmoidoscopies do you
perform?
7. During an average week, how many sigmoidoscopies are 
performed in your practice?
8. How many additional screening colonoscopies could your
practice perform in a week?
9. How many additional screening sigmoidoscopies could your
practice perform in a week?
10. What resources would be required to perform additional endo-
scopic procedures?
None More More More More Other
equipment space support staff physicians
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Table 2. Current Volume of Colonoscopies Performed Weekly and Weekly Capacity for Additional Colonoscopies, New Mexico,
2001
Table 3. Number of Colonoscopies Required to Increase the Prevalence of Current Screening During a Five-Year Period for
New Mexico Adults Aged 50 to 85 Years
aIncludes numbers of screening tests based on 2000 New Mexico census data and numbers of surveillance tests based on applying cancer (1.0%) and
adenomatous polyp (37%) detection rates from a Department of Veterans Affairs (VA) study (28).
bIncludes numbers of screening tests based on 2000 New Mexico census data and numbers of surveillance tests based on applying cancer (0.5%) and
adenomatous polyp (20%) detection rates from sensitivity analysis.
cNumbers in parentheses reflect the strategy of performing a three-year surveillance colonoscopy on all patients with adenomatous polyps compared to five-
year surveillance interval.
Table 4. Barriers to Performing Additional Endoscopic Tests, Results of a Survey of Gastroenterologists, New Mexico, 2001a
None 1 4 
More equipment 4 2 
More space 8 1 
More support staff 7 3 
More physicians 8 4 
Other (lack of referrals) 1 0 
aMore than one barrier could be reported.
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aValues are median (interquartile range).
bNA = not applicable.
Practice Type Total Current
number of colonoscopies Total current Additional Total additional
endoscopists per endoscopista colonoscopies colonoscopies colonoscopies
Group 40 16.3 (12.9, 26.5) 652 6.3 (1.8, 10) 252
Solo 9 20 (15, 21) 180 10 (5, 15) 90
Combined 49 NAb 832 NA 342
Annual number of colonoscopies Annual number of colonoscopies
Screening increase over five years (%) (based on detection rates from VA study)a (based on detection rates from sensitivity analysis)b
5 5568 (5983)c 5137 (5360)
10 11,136 (11,966) 10,274 (10,721)
15 16,704 (17,949) 15,411 (16,082)
20 22,272 (23,932) 20,548 (21,442)
25 27,840 (29,915) 25,568 (26,800)
Group practices Solo practitioners
Barrier N = 11 N = 9 
